Gilead Sciences, Inc. $GILD Shares Purchased by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 397.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,748,403 shares of the biopharmaceutical company’s stock after acquiring an additional 5,392,191 shares during the quarter. Ameriprise Financial Inc.’s holdings in Gilead Sciences were worth $748,147,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sivik Global Healthcare LLC boosted its stake in Gilead Sciences by 25.0% during the 2nd quarter. Sivik Global Healthcare LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $5,544,000 after purchasing an additional 10,000 shares in the last quarter. One Wealth Advisors LLC lifted its stake in Gilead Sciences by 34.8% during the second quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after buying an additional 2,364 shares in the last quarter. Invesco Ltd. lifted its position in shares of Gilead Sciences by 33.5% in the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Ariel Investments LLC boosted its position in shares of Gilead Sciences by 7.7% in the first quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock worth $48,229,000 after buying an additional 30,630 shares during the period. Finally, Simplify Asset Management Inc. grew its stake in Gilead Sciences by 148.6% during the 2nd quarter. Simplify Asset Management Inc. now owns 52,890 shares of the biopharmaceutical company’s stock valued at $5,864,000 after acquiring an additional 31,618 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group raised their price target on Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a research report on Monday, November 3rd. Scotiabank assumed coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 target price for the company. Finally, Needham & Company LLC lifted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.13.

Gilead Sciences Price Performance

Gilead Sciences stock opened at $120.40 on Friday. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $149.38 billion, a P/E ratio of 18.67, a PEG ratio of 0.68 and a beta of 0.32. The business has a 50-day moving average of $121.89 and a 200-day moving average of $115.71.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Insiders Place Their Bets

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares in the company, valued at $170,186.90. This trade represents a 67.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the sale, the chief financial officer owned 154,555 shares of the company’s stock, valued at approximately $19,354,922.65. The trade was a 1.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 135,757 shares of company stock worth $16,616,127 in the last three months. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.